Etodolac is a nonsteroidal antiinflammatory drug used to relieve pain and inflammation. It works by inhibiting the cyclooxygenase enzymes that synthesize prostaglandins. Prostaglandins are signaling molecules that promote fever, swelling, and sensitivity in tissues. By reducing prostaglandin production the medication diminishes these physiological responses. The active compound selectively blocks cox-2 more than cox-1, which helps spare the gastrointestinal lining. Inhibition of cox-2 decreases the formation of inflammatory mediators that cause swelling and joint discomfort. This action leads to improved mobility and reduced discomfort during daily activities. The overall effect of the drug is a modest analgesic and antiinflammatory response that supports symptomatic management.

Etodolac is a nonsteroidal anti-inflammatory drug classified as a selective cyclooxygenase-2 inhibitor. It is used clinically to relieve mild to moderate pain and inflammation associated with conditions such as arthritis. Pharmacodynamically the agent reduces the synthesis of prostaglandins by binding to the cox-2 enzyme in inflamed tissues. This selective inhibition limits the production of inflammatory mediators while sparing normal physiological cox-1 activity. The resulting decrease in prostaglandin levels leads to lower fever, reduced swelling, and diminished nociceptive signaling. Pharmacokinetically the drug is rapidly absorbed after oral administration and undergoes extensive hepatic metabolism before renal excretion. Metabolites of Etodolac retain some pharmacological activity but contribute to its overall duration of action. Clinically the medication provides analgesic and antipyretic effects comparable to other nsaids with a favorable safety profile in short-term use.

Etodolac can cause gastrointestinal discomfort such as nausea or indigestion. It may increase the risk of headache or dizziness in some patients. Swelling in the lower legs or feet can occur as a sign of fluid retention. Elevated liver enzymes are sometimes observed during treatment. Skin reactions such as rash or itching may develop in certain individuals. Rarely, blood pressure may rise which requires monitoring. Some people experience abdominal pain or heartburn while taking the medication. In uncommon cases visual disturbances have been reported.

Etodolac may cause dizziness or light-headedness in some users. It can also lead to gastrointestinal discomfort such as nausea or constipation. Some individuals experience headache or skin rash as a reaction. Occasionally, the medication is associated with increased blood pressure or fluid retention. Rarely, liver enzyme elevations can occur without obvious symptoms. These effects are generally mild and transient, but they can vary among patients.